ProCE Banner Activity

HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon

Slideset Download
Get up to date on current and emerging HER2-targeted TKIs and antibody–drug conjugates for HER2-positive metastatic breast cancer across multiple lines of therapy.

Released: June 30, 2020

Expiration: June 29, 2021

Share

Faculty

Neelima Denduluri

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Puma Biotechnology, Inc.

Seagen

Faculty Disclosure

Primary Author

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia